Literature DB >> 18003803

Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.

George Sakoulas1, Warren Rose, Michael J Rybak, Satish Pillai, Jeff Alder, Robert C Moellering, George M Eliopoulos.   

Abstract

We examined sequential methicillin-susceptible Staphylococcus aureus isolates from a patient with mitral valve endocarditis recovered during persistent bacteremia on standard therapy and relapse after treatment with daptomycin. An isolate obtained after 5 days of antimicrobial therapy, but before exposure to daptomycin, showed subtle physiological changes in response to daptomycin, with significant regrowth in the daptomycin killing assay compared to the treatment-naive strain. Once daptomycin was started, the population became more heterogeneous and tested as nonsusceptible. These organisms were examined in a simulated-vegetation in vitro pharmacodynamic model, which confirmed progressive decreases in killing with daptomycin concentrations that simulate those attained in humans with 6-mg/kg of body weight daily dosing. Early surgical intervention or combination therapy or both might have prevented the loss of daptomycin susceptibility.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18003803      PMCID: PMC2224245          DOI: 10.1128/JCM.00660-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  In vitro bactericidal activity of daptomycin against staphylococci.

Authors:  Peter C Fuchs; Arthur L Barry; Steven D Brown
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

2.  Teicoplanin stress-selected mutations increasing sigma(B) activity in Staphylococcus aureus.

Authors:  M Bischoff; B Berger-Bächi
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  R L Akins; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  George Sakoulas; George M Eliopoulos; Jeff Alder; Claudie Thauvin Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Richard P Novick; Lata Venkataraman; Christine Wennersten; Paola C DeGirolami; Mitchell J Schwaber; Howard S Gold
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

6.  Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Christine Wennersten; Lata Venkataraman; Richard P Novick; Howard S Gold
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

Authors:  Laura A Jevitt; Amanda J Smith; Portia P Williams; Patti M Raney; John E McGowan; Fred C Tenover
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

8.  The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

Authors:  Robert D Arbeit; Dennis Maki; Francis P Tally; Edward Campanaro; Barry I Eisenstein
Journal:  Clin Infect Dis       Date:  2004-05-20       Impact factor: 9.079

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.

Authors:  Jennifer M Streit; Ronald N Jones; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2004-02-25       Impact factor: 5.790

View more
  19 in total

1.  Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.

Authors:  Zukile Gqada; Ben Marais; Elizabeth Wasserman; Colleen Bamford; Heidi Orth; George Sakoulas; Warren Rose; Michael J Rybak; Satish Pillai; Jeff Alder; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2008-07       Impact factor: 5.948

2.  Comparative efficacies of cloxacillin-daptomycin and the standard cloxacillin-rifampin therapies against an experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.

Authors:  Cristina El Haj; Oscar Murillo; Alba Ribera; Mireia Vivas; Dolors Garcia-Somoza; Fe Tubau; Javier Cabo; Javier Ariza
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation.

Authors:  Ute Bertsche; Christopher Weidenmaier; Daniel Kuehner; Soo-Jin Yang; Stefanie Baur; Stefanie Wanner; Patrice Francois; Jacques Schrenzel; Michael R Yeaman; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2011-05-23       Impact factor: 5.191

Review 4.  Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature.

Authors:  S J van Hal; D L Paterson; I B Gosbell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-30       Impact factor: 3.267

5.  Methicillin-resistant Staphylococcus aureus endocarditis and de novo development of daptomycin resistance during therapy.

Authors:  L Twele; E Moyen; K Zhang; B Dalton; D Church; J Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

6.  Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE).

Authors:  B A Cunha; F M Pherez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-28       Impact factor: 3.267

7.  Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains.

Authors:  Soo-Jin Yang; Yan Q Xiong; Paul M Dunman; Jacques Schrenzel; Patrice François; Andreas Peschel; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

Review 8.  Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Authors:  Mukesh Patel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.

Authors:  Jordan R Smith; Anu Arya; Juwon Yim; Katie E Barber; Jessica Hallesy; Nivedita B Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Warren E Rose; Steven N Leonard; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.